Vancouver, British Columbia - TheNewswire - September 12, 2023 - Cava Healthcare Inc. (the “Company”) is excited to share that Chief Scientific Officer, Professor Wilfred Jefferies and his collaborators have authored two research papers. Several aspects of this research are now protected by patents and patent applications.

The first paper, entitled “A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours”, reports a high-throughput screening method for efficient discovery of novel anticancer agents. Screening of a library of 480 marine invertebrate extracts followed by bioassay-guided fractionation, led to the identification of curcuphenol, a common sesquiterpene phenol also derived from turmeric, as the active compound of one of the extracts. The paper demonstrates curcuphenol induces expression of the genes in both metastatic prostate and lung carcinomas making them more visible to the immune system.

See https://www.frontiersin.org/articles/10.3389/fphar.2023.1119607/full

The second paper, entitled “Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours”, reports the creation synthetic curcuphenol analogues prepared by informed design that demonstrate consistent induction of genes in both metastatic prostate and lung carcinomas. Both analogues were discovered to have a previously unknown ability to enhance histone deacetylase (HDAC) activity that epigenetically modifies the cancer genome leading to gene expression that rendering tumours more visible to the immune system. See https://www.frontiersin.org/articles/10.3389/fphar.2023.1119620/full

The Company reports that its Board of Directors has accepted the resignation of James Borkowski as Director and thanks Mr. Borkowski for his service. Mr. Borkowski will remain an Advisor to the Company.

The Company is delighted to announce the appointment of Mr. Lih Ming Tam, as a Director. Mr. Lih Ming Tam is an experienced business leader who is currently Director (Operations) and CFO at Green Light Innovation Partners Inc., a 25-year-old professional services firm led by successful entrepreneurs, known for their innovation, funding, and business growth expertise. Mr. Tam has excelled in working with companies of all sizes, including startups, private investors, public ventures, venture capital, and joint ventures, earning trust through performance excellence and has helped raise over $65 million (Canadian) in financing in the past decade.

The Company further reports that Mr. Theo Warkentin has resigned as CEO and thanks Mr. Warkentin for his service. He will remain a Director of the Company.

For further information, please contact Adrian Wade at adrian@cavahealthcare.ca or (604) 370‑1757.

On Behalf of the Board of Directors

Adrian Wade, Ph.D.
COO and Director

CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE

Cava is a specialty biotechnology company focused on advancing drug development to address unmet medical needs in neurodegeneration, inflammation, and restoration of immune function.  The Company has a patent protected portfolio of intellectual property and technology, concentrated on the development of a treatment for Alzheimer’s Disease and various oncology related biomarkers and treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995.  All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future including, without limitation, matters related to the Company’s current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans.  Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved.  Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities.  Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company.  These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.  Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate.  Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.  These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.